Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987473 | 0.81 | ALOX15 (0.52) | TTRSNCAKDM4EGAAMAPT | |
| SCHEMBL1390986 | 0.81 | ALOX15 (0.52) | TTRSNCAKDM4EGAAMAPT | |
| SCHEMBL4497180 | 0.81 | SNCA (0.44) | SNCAKDM4EGAAMAPTALDH1A1 | |
| SCHEMBL29875658 | 0.80 | CA2 (0.38) | TTRCA2CA1CA4CA6 | |
| SCHEMBL1045835 | 0.80 | CA2 (0.38) | TTRCA2CA1CA4CA6 | |
| SCHEMBL8227732 | 0.79 | SNCA (0.42) | SNCAKDM4EGAAMAPTALDH1A1 | |
| SCHEMBL31511762 | 0.79 | TTR (0.43) | TTRSNCAKDM4EGAAMAPT | |
| SCHEMBL13163675 | 0.79 | ABAT (0.46) | SNCAKDM4EGAAMAPTALDH1A1 | |
| SCHEMBL10208289 | 0.79 | TRPA1 (0.64) | SNCAKDM4EMAPTALDH1A1CA2 | |
| Hydrochloric Acid SCHEMBL22418989 | 0.77 | MAPT (0.45) | SNCAKDM4EGAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025119216-A1 | BORONIC ACID β-LACTAMASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 珠海联邦制药股份有限公司 | 2025-06-12 | — | — | WO | disclosed |
| CN-119948034-A | Novel peptide-based nitrile compound and application thereof | 上海壹迪生物技术有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| CN-119504706-A | Macrocyclic compounds having farnesyl transferase inhibitory activity | 库拉肿瘤学公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2025001407-A1 | POLYARYL-CONTAINING MACROCYCLIC COMPOUNDS AND USES THEREOF | 浙江养生堂天然药物研究所有限公司 | 2025-01-02 | — | — | WO | disclosed |
| CN-119219930-A | Drug-loaded macromolecules, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119192199-A | Polyaryl-containing macrocyclic compounds and uses thereof | 浙江养生堂天然药物研究所有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
| US-6555663-B1 | Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule | MILLS RANDELL LEE (US) | 2003-04-29 | — | — | US | disclosed |
| CN-1089086-C | Luminandide medicine | MILLS RANDELL L (US) | 2002-08-14 | — | — | CN | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| CN-1047075-A | Luminandide medicine | MILLS RANDELL L (US) | 1990-11-21 | — | — | CN | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | TTR 3734/4885SNCA 3972/4885KDM4E 3072/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | TTR 2766/4885SNCA 716/4885KDM4E 1725/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | TTR 1923/4885SNCA 4283/4885KDM4E 4509/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | TTR 1034/4885SNCA 3448/4885KDM4E 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.